Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

New England Journal of Medicine

Volumn 345, Issue 4, 2001, Pages 241-247

  Kreitman, Robert J ^a   Wilson, Wyndham H ^a   Bergeron, Karen ^a   Raggio, Miranda ^a   Stetler Stevenson, Maryalice ^a   Fitzgerald, David J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BL 22; CD103 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; FLUDARABINE; GLYCOPROTEIN P 15095; IMMUNOTOXIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; NEUTRALIZING ANTIBODY; PENTOSTATIN; PSEUDOMONAS EXOTOXIN; RICIN; RITUXIMAB; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOGENICITY; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MINIMAL RESIDUAL DISEASE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RELAPSE; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES; ANTINEOPLASTIC AGENTS; CLADRIBINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENTEROTOXINS; EXOTOXINS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOTOXINS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; PSEUDOMONAS; RECURRENCE; REMISSION INDUCTION;

EID: 0035954624     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107263450402     Document Type: Article

References (43)

1. Leukemic reticuloendotheliosis
2. Epidemiology of hairy cell leukemia in Los Angeles County
3. Hairy cell leukemia: Clinical presentation and follow-up of 211 patients
4. Hairy cell leukemia: A clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL)
5. The history of hairy cell leukemia: Characteristics of long-term survivors
6. Remissions in hairy-cell leukemia with pentostatin (2′deoxycoformycin)
7. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
8. Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients
9. Alpha interferon for induction of remission in hairy-cell leukemia
10. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study
11. Treatment of hairy-cell leukemia: Current views
12. Long term results with 2′deoxycoformycin in hairy cell leukemia
13. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
14. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine - A report of three cases
15. Phase I immunotoxin trial in patients with B-cell lymphoma
16. CD22, a B cell-specific receptor, mediates adhesion and signal transduction
17. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia
18. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia
19. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)
20. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
21. Continuous infusion of the anti-CD22 immunotoxin IgG-RYB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
22. Immunotoxins in cancer therapy
23. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RYB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys
24. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemia
25. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
26. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse
27. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
28. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia
29. Hairy cell leukemia variant treated with success by 2-chlorodeoxyadenosine
30. Treatment of hairy cell leukemia-variant (HCL-V) with cladribine
31. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia
32. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine
33. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission
34. Disease eradication in hairy cell leukemia patents treated with 2-chlorodeoxyadenosine
35. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia
36. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-Year follow-up
37. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
38. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
39. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
40. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration
41. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
42. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
43. Y damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome